Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830753 | 0.93 | CRBN (0.55) | CRBNDDB1GPR119POLBHRH3 | |
| SCHEMBL30830575 | 0.88 | DDB1 (0.61) | CRBNDDB1GPR119HRH3 | |
| SCHEMBL25074070 | 0.87 | DDB1 (0.60) | CRBNDDB1GPR119 | |
| SCHEMBL30201818 | 0.87 | DDB1 (0.60) | CRBNDDB1GPR119 | |
| SCHEMBL25187964 | 0.87 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL23301622 | 0.87 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL24206650 | 0.87 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL30831101 | 0.86 | DDB1 (0.54) | CRBNDDB1GPR119HRH3CHEK2 | |
| SCHEMBL30830933 | 0.86 | CRBN (0.55) | CRBNDDB1GPR119POLBCHEK2 | |
| SCHEMBL30830790 | 0.85 | DDB1 (0.55) | CRBNDDB1GPR119HRH3CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | CRBN 688/4885DDB1 1230/4885GPR119 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.